Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up
Main Article Content
Keywords
cemiplimab
References
2. Monroe M et al. Otolaryngol Clin North Am. 2021;54:271–280.
3. Sekulic A et al. N Engl J Med. 2012;366:2171–2179.
4. Migden MR et al. Lancet Oncol. 2015;16:716–728.
5. Basset-Seguin N et al. Lancet Oncol. 2015;16:729–736.
6. Burova E et al. Mol Cancer Ther. 2017;16:861–870.
7. Regeneron Pharmaceuticals, Inc. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf. [Accessed January 22, 2022].
8. Regeneron Pharmaceuticals, Inc. Available at: https://www.prnewswire.com/news-releases/libtayo-cemiplimabapproved-by-the-european-commission-as-the-first-immunotherapy-indicated-for-patients-with-advanced-basalcell-carcinoma-301319988.html. [Accessed January 22, 2022].
9. Health Canada. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/libtayo-notice-compliance-conditions-218718.html. [Accessed January 22, 2022].
10. Ministry of Health Israel. Available at: https://israeldrugs.health.gov.il/#!/medDetails/164%2099%2036023%2000. [Accessed January 22, 2022].
11. Brazilian Health Authority - ANVISA. Available at: https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novosmedicamentos-e-indicacoes/libtayo-cemiplimabe-nova-indicacao. [Accessed January 22, 2022].
12. Stratigos AJ et al. Lancet Oncol. 2021;22:848–857.
13. Lewis K et al. J Immunother Cancer. 2020;8:Abstract 428.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.